Selecta Biosciences
480 Arsenal Way
Building One
Watertown
Massachusetts
02472
United States
Tel: 617-923-1400
Fax: 617-924-3454
Website: http://www.selectabio.com/
Email: info@selectabio.com
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.
Stock Symbol: SELB
Exchange: NASDAQ
160 articles with Selecta Biosciences
-
BioSpace Movers and Shakers, July 19
7/19/2019
Pharma and biotech companies from across the globe expand their leadership teams and boards. -
Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer
7/15/2019
Alison is an extremely accomplished senior leader with over 20 years of combined drug development, strategic management and practical clinical experience in academia and industry, successfully leading multiple clinical programs to approval
-
Selecta Biosciences announced that as part of restructuring efforts it is cutting its current workforce by 36 percent. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent.
-
Bioscience Companies Deliver Life-Changing Products to Patients Faster with Help from NetSuite
8/13/2018
To accelerate the commercialization of life-changing products, bioscience companies are selecting Oracle NetSuite.
-
Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage trial that showed a significant reduction of serum uric acid at 12 weeks.
-
Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in PNAS Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined With SVP-Rapamycin
1/9/2018
In the PNAS publication, the authors described preclinical work in which SVP-Rapamycin mitigated the formation of inhibitory ADAs to LMB-100 in both naïve mice and mice pre-exposed to LMB-100, resulting in restoration of LMB-100’s anti-tumor activity.
-
Selecta Biosciences Announces FDA Acceptance of IND Application for LMB-100 and SVP-Rapamycin Com...
1/2/2018
SVP-Rapamycin is Selecta’s proprietary, clinical-stage anti-drug antibody (ADA) prevention and immune tolerance technology. -
Werner Cautreels, Ph.D., intends to retire effective December 31, 2018.
-
Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
11/7/2017
For the third quarter of 2017, the company’s total revenue was less than $0.1 million, which compares with $1.0 million for the third quarter of 2016.
-
Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017
10/31/2017
t 8:30 a.m. ET that day, Selecta will host a conference call to discuss these results and provide a corporate update.
-
Selecta Biosciences Announces Important Additions to Senior Leadership Team
10/26/2017
The company announced two additions to its management team today.
-
Selecta Announces Second Quarter 2017 Financial Results And Provides Corporate Update
8/11/2017
-
Selecta To Report Second Quarter 2017 Financial Results On Friday, August 11, 2017
8/4/2017
-
Massachusetts' Selecta Banks $50 Million
6/26/2017
-
Selecta Announces Addition Of Patrick J. Zenner To Board Of Directors
6/19/2017
-
Selecta Reports Data From Ongoing Phase II Trial Of Lead Candidate, SEL-212, In Development For Chronic Severe Gout
6/15/2017
-
Lyophilization Services of New England Contract Manufacturing Announces Manufacturing Agreement With Selecta
5/24/2017
-
Selecta Commences Dosing In Phase I Clinical Trial Of Nicotine Vaccine For Smoking Cessation And Relapse Prevention
5/12/2017
-
Selecta Announces First Quarter 2017 Financial Results And Provides Corporate Update
5/12/2017
-
Selecta To Report First Quarter 2017 Financial Results On Thursday, May 11, 2017
5/4/2017